Kenneth D Westover
Overview
Explore the profile of Kenneth D Westover including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
4332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Z, Westover K
Cancer Discov
. 2025 Mar;
15(3):455-457.
PMID: 40025947
This issue highlights the development of a first-in-class small-molecule covalent KRASG12C inhibitor, BBO-8520, which targets both the active (ON) and inactive (OFF) states of KRAS. This dual-state targeting offers a...
2.
Zhang Y, Laine A, Iyengar P, Westover K, Dowell J, Hughes R, et al.
Int J Radiat Oncol Biol Phys
. 2025 Feb;
PMID: 39922319
Purpose: We investigated the efficacy and toxicity of thoracic radiation therapy (RT) plus concurrent and consolidation carboplatin with either solvent-based paclitaxel (sb-paclitaxel) or solvent-free nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Methods And...
3.
Kramer-Drauberg M, Petrini E, Mira A, Patrucco E, Scardaci R, Savinelli I, et al.
Mol Oncol
. 2025 Jan;
19(2):311-328.
PMID: 39838816
Specific reactive oxygen species activate the GTPase Kirsten rat sarcoma virus (KRAS) by reacting with cysteine 118 (C118), leading to an electron transfer between C118 and nucleoside guanosine diphosphate (GDP),...
4.
Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, et al.
Sci Adv
. 2024 Dec;
10(50):eadq4274.
PMID: 39661665
Direct targeting of the -mutant protein using covalent inhibitors (G12Ci) acts on human non-small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we...
5.
Chen Y, Yin Z, Westover K, Zhou Z, Shu L
Mol Cancer Ther
. 2024 Oct;
24(1):33-46.
PMID: 39404173
RAS mutations are prevalent in leukemia, including mutations at G12, G13, T58, Q61, K117, and A146. These mutations are often crucial for tumor initiation, maintenance, and recurrence. Although much is...
6.
Zhou Z, Nguyen T, Li X, Poujol C, Berlinska E, Michelina S, et al.
J Biol Chem
. 2024 Oct;
300(11):107859.
PMID: 39374781
RAS clustering at the cell membrane is critical to activate signaling in cells, but whether this clustering is mediated exclusively by its c-terminal hypervariable region, receives contributions from the G-domain...
7.
Zhang Y, Iyengar P, Montalvo S, Westover K, Rashdan S, Donthireddy K, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):68-74.
PMID: 39147210
Purpose: Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) immune checkpoint inhibitor, administered after concurrent chemoradiation improves outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) without substantially...
8.
Meyer C, McCoy M, Li L, Posner B, Westover K
Cell Rep Phys Sci
. 2024 Jan;
4(10).
PMID: 38213501
Measurements of kinase activity are important for kinase-directed drug development, analysis of inhibitor structure and function, and understanding mechanisms of drug resistance. Sensitive, accurate, and miniaturized assay methods are crucial...
9.
Chen X, Li Y, Zhou Z, Zhang Y, Chang L, Gao X, et al.
Cancer Med
. 2023 Oct;
12(19):19904-19920.
PMID: 37792675
Background: Prolonged treatment of HER2+ breast cancer with lapatinib (LAP) causes cellular senescence and acquired drug resistance, which often associating with poor prognosis for patients. We aim to explore the...
10.
Yu D, Zhao J, Lee E, Kim D, Mahapatra R, Rose E, et al.
J Clin Invest
. 2023 Sep;
133(21).
PMID: 37721853
The facilitative GLUT1 and GLUT3 hexose transporters are expressed abundantly in macrophages, but whether they have distinct functions remains unclear. We confirmed that GLUT1 expression increased after M1 polarization stimuli...